LEVIMMUNE
Dead / Abandoned — Abandoned — no statement of use filed (as of 07 Mar 2022)
What this means for you
This application is over — abandoned 07 Mar 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88751609
- Mark type
- Stylized text
- Filed
- 08 Jan 2020
- Published for opposition
- 09 Jun 2020
- Abandoned
- 07 Mar 2022
- Attorney of record
- Jared M. Barrett
Goods and services
- Class 005 — Pharmaceuticals: Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor
- Class 042 — Scientific and technological services: Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor
- Class 044 — Medical, beauty and agricultural services: Providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
Owner
- CytoDyn Inc., Vancouver, WA, US
- CytoDyn Inc., Vancouver, WA, US
Prosecution history
- 07 Mar 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 07 Mar 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 15 Jul 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Jul 2021 — SOU EXTENSION 2 GRANTED
- 13 Jul 2021 — SOU EXTENSION 2 FILED
- 13 Jul 2021 — SOU TEAS EXTENSION RECEIVED
- 12 Jan 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jan 2021 — SOU EXTENSION 1 GRANTED
- 08 Jan 2021 — SOU EXTENSION 1 FILED
- 08 Jan 2021 — SOU TEAS EXTENSION RECEIVED
- 04 Aug 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 09 Jun 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jun 2020 — PUBLISHED FOR OPPOSITION
- 20 May 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 04 May 2020 — ASSIGNED TO LIE